SHOUGANG LANZA (02553) has been included in the Hang Seng Composite Index and is expected to become a constituent of the Hong Kong Stock Connect.

On August 21, 2026, Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of June 30, 2026, in which SHOUGANG LANZA (02553) was included in the Hang Seng Composite Index. The changes to the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect starting September 7 (Monday), at which point the Shanghai and Shenzhen exchanges will accordingly adjust the scope of investable stocks under the Hong Kong Stock Connect. SHOUGANG LANZA may be included in the Hong Kong Stock Connect as it meets a series of criteria including market capitalization and liquidity. Recently, CITIC SEC released a research report that initiates coverage on SHOUGANG LANZA with a "Buy" rating and a target price of up to HKD 44, representing a 66.79% upside potential compared to the report's release price of HKD 26.38. As new projects gradually come into production, the company's expected operating revenues for 2026, 2027, and 2028 are projected to be RMB 657 million, RMB 860 million, and RMB 1.546 billion respectively. As a leading player in AI synthetic biology CCUS, the company faces short-term performance pressure due to fluctuations in gas sources and ethanol prices; however, as products mature and capacity continues to recover at the four major bases, the company is expected to alleviate gas source constraints through its park gas supply projects, and a technical licensing model opens up growth avenues. Coupled with the iterative upgrades of first and second generation core technologies and supportive policy benefits, new business lines such as SAF, green polyethylene, and bioactive peptides are progressing simultaneously, providing ample development space in the medium to long term.